Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the market benchmark within the next six months [16]. Core Views - The company reported Q3 2024 revenue of 2.15 billion (up 4.68%) and a net profit of 238 million (up 17.02%), with a year-to-date revenue of 6.14 billion (up 2.65%) and a net profit of 641 million (up 17.42%) [1][3]. - The consolidation of Baiyang Pharmaceutical into the financial statements is expected to provide new growth momentum, with performance commitments of not less than 140 million, 170 million, and 220 million for the years 2024-2026 [1]. - The brand operation business achieved revenue of 4.13 billion (up 15.5%) in the first three quarters, with a gross profit of 2.02 billion (up 19.26%), maintaining steady growth [3]. - The company is focusing on core brand operations while reducing the scale of its wholesale and distribution business, which saw a revenue decline of 19.4% [2][3]. - The company is expected to continue expanding into new product categories, with revenue projections of 8.2 billion, 9.5 billion, and 10.7 billion for 2024-2026, reflecting growth rates of 8%, 16%, and 13% respectively [1][3]. Financial Summary - The company’s net profit for 2024 is projected to be 870 million (up 32%), with earnings per share (EPS) expected to reach 1.65 [5][11]. - The financial data indicates a steady increase in revenue and net profit over the years, with a projected net profit of 1.48 billion in 2026 [5][14]. - The company’s price-to-earnings (P/E) ratio is expected to decrease from 23.2 in 2023 to 10.3 in 2026, indicating improved valuation over time [5][14].
百洋医药：业绩符合预期，制药并表提供新增长动能